DBS study could boost Medtronic's neuromodulation business

June 3, 2010 by MedCity News

A study showing that deep-brain stimulation helped treat patients with Parkinson's disease could prove to be a boon for Medtronic Inc.'s growing neuromodulation business.

MedCity News logo

By Thomas Lee

The conclusions from a major study on deep-brain stimulation published in the New England Journal of Medicine today seemed rather anti-climatic, at least on the surface.

There was no real difference between implanting a DBS device in the globus pallidus interna and subthalamic nucleus regions of the brains in patients suffering from Parkinson’s disease. Each worked equally as well.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.